Agreements (Details 8) (USD $)	3 Months Ended								12 Months Ended			1 Months Ended	12 Months Ended	1 Months Ended				12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jan. 31, 2014 CytomX	Jun. 30, 2014 CytomX	Jan. 31, 2014 CytomX Future Technological Improvements	Jan. 31, 2014 CytomX Research Services	Jan. 31, 2014 CytomX Right-to-test agreement	Jan. 31, 2014 CytomX Development and Commercialization License	Jun. 30, 2014 CytomX Development and Commercialization License	Jan. 31, 2014 CytomX Development and Commercialization License Maximum	Jan. 31, 2014 CytomX Development and Commercialization License Development milestones	Jan. 31, 2014 CytomX Development and Commercialization License Development milestones Phase I clinical trial	Jan. 31, 2014 CytomX Development and Commercialization License Regulatory milestones	Jan. 31, 2014 CytomX Development and Commercialization License Sales milestones
Collaborative Agreements disclosures
Upfront payments received under collaboration agreement																$ 0
Potential milestone payments receivable																			160,000,000	10,000,000	1,000,000	50,000,000	100,000,000
Potential milestone payments to be paid																			80,000,000	7,000,000	1,000,000	23,000,000	50,000,000
Discount rate (as a percent)																		13.00%
Estimated utilization period after commercialization																		10 years
Fair value of consideration for services provided												13,100,000		350,000	140,000	13,000,000	12,700,000
Estimated term of development and commercialization license																		25 years
License fee revenue	305,000	305,000	25,678,000	13,167,000	855,000	22,010,000	429,000	933,000	39,455,000	24,227,000	9,161,000		0
Arrangement consideration included in long-term deferred revenue	58,969,000				63,384,000				58,969,000	63,384,000			13,000,000
Fair value of consideration for services received														$ 310,000	$ 12,800,000